Rasagiline

Drug #2342

Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson’s disease or as an adjunct therapy in more advanced cases

← Previous drug Next drug →

Primary Characteristics

It is of Combo1 origin and belongs to indanes..

Molecular Weight: 171.24 · Solubility in Water: 3,700 mg/L · Non-proprietary name: Rasagiline.

Pharmacokinetics

Distribution: Rasagiline has a volume of distribution is 87 L. plasma protein binding is 88 – 94%.

Elimination: it is metabolised via Hepatic (CYP1A2-mediated, plasma half-life is 3hr.

Indications

Rasagiline is primarily indicated in conditions like Parkinson's disease.

Rasagiline is also indicated for secondary conditions like Adjunctive therapy.

Contraindications

None recorded.

Dosage

None recorded.

Drug Interactions

None recorded.

Side Effects

The signs and symptoms that are produced after acute overdosage of Rasagiline are flu syndrome, Depression , Indigestion, jOINT pAIN, Joint Pain.

Warnings / Precautions

Do not take AZILECT if you are taking meperidine as it could result in a serious reaction such as coma or death. Also, do not take AZILECT with tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, or cyclobenzaprine. You also should not take AZILECT with other monoamine oxidase inhibitors (MAOIs), as it could result in an unsafe rise in blood pressure. Increases in blood pressure may occur during treatment with AZILECT. Inform your physician if you have a history of high blood pressure. Possible symptoms of an unsafe rise in blood pressure include severe headache, blurred vision, difficulty thinking, seizure, chest pain, and nausea/vomiting.

Available Brands

None recorded.